NurExone Biologic

Exo-Top, NurExone’s wholly owned U.S. subsidiary, entered into a binding MOU with ExoLyra for the distribution of naïve MSC-derived exosome products in Mexico.

The agreement marks Exo-Top’s first structured commercial entry and supports NurExone’s dual-track strategy: near-term exosome commercialization alongside continued ExoPTEN therapeutic development.

Read More: https://www.globenewswire.com/news-release/2026/06/24/3317189/0/en/exo-top-nurexone-s-wholly-owned-u-s-subsidiary-enters-into-binding-mou-for-na%c3%afve-exosome-distribution-in-mexico.html

Learn more about Exo-Top: https://nurexone.com/exo-top/